WuXi Biologics Wins Multiple Asia-Pacific Biopharma Awards
WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won six prestigious awards and two...
Category : Clinical Research, Pharma & Healthcare Financing
NervGen Pharma Voluntarily Delists from TSX Venture
NervGen Pharma Corp. (“NervGen” or the “Company”) (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and...
Combat Medical Raises £2.6M for Bladder Cancer Treatment
Combat Medical (Combat), a medical device company optimising the delivery and efficacy of cancer therapeutics, today announced it has raised £2.6 million in the first...
Personalis Study Advances Breast Cancer Treatment Monitoring
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of the PREDICT-DNA study in the Journal of Clinical Oncology....
Meiji Seika Starts Phase I Trial for ME3241 in Australia
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) announced today that it has initiated a Phase I clinical...
GenomOncology Partners with WeTrials to Speed CNS Trials
GenomOncology, a leading precision medicine software company, today announced a strategic partnership with WeTrials, an AI-powered patient engagement and trial enablement platform, to help CNS...
ARTHEx Biotech Gets FDA Fast Track for ATX-01 in DM1
ARTHEx Biotech, a clinical-stage biotechnology company advancing RNA-based therapeutics for neuromuscular disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
QuantHealth Reports 8x Growth in Life Sciences Engagements
The Company Has Established the Industry’s Most Advanced Portfolio of Clinical Trial Simulation Capabilities for Pharmaceutical and Biotechnology Companies QuantHealth, a pioneer in AI-driven clinical...
C-Further Unveils First Pediatric Oncology Therapeutics
C-Further to advance its first two bespoke paediatric cancer therapeutics in collaboration with leading global academic and industry investigators Selected programmes to potentially address multiple...
Alzheon to Present ALZ-801 Trial Results at 2026 AD/PD
Alzheon Reports Valiltramiprosate Shows Promise as an Oral Potentially Disease-Modifying Agent to Slow Alzheimer’s Disease Based on Clinical, MRI, and Biomarker Data in APOE4/4 MCI...
Belite Bio Reports Preliminary FY2025 Financial Results
Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that...
BioXcel Reports Positive Phase 2 Results for BXCL501
BXCL501 demonstrated clinical benefits and favorable tolerability profile for treatment of opioid withdrawal symptoms Results from this NIDA-funded study support potential future development of BXCL501...
Curanex Announced the Formation of World Class Scientific Advisory Board
Board Includes Former Fortune 100 Pharma Executive and Leading US Medical Research Academic Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a development-stage pharmaceutical...
XyloCor Appoints John Tucker as President and CEO
XyloCor Therapeutics, Inc. (XyloCor or the Company), a clinical-stage biopharmaceutical company focused on developing innovative therapies for cardiovascular disease, today announced the appointment of John...
Azenta Acquires UK Biocentre Limited, to Expand Biorepository Capabilities
Azenta, Inc. (Nasdaq: AZTA), a leading provider of life science solutions, today announced that its wholly owned subsidiary, Azenta UK Ltd, has acquired UK Biocentre Limited,...